We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Ultragenyx (RARE - Free Report) shares ended the last trading session 12.6% higher at $14.5. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 50.9% loss over the past four weeks.
Shares moved higher following the FDA’s full approval of Ultragenyx’s Fayuvi (rebisufligene etisparvovec-hopf), also known as UX111, for treating the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A) in pediatric patients with preserved neurodevelopmental function. The approval makes Fayuvi the first FDA-approved treatment for this rare and fatal neurodegenerative disorder and marks RARE’s second gene therapy approval and sixth FDA approval overall. The approval was supported by nearly eight years of clinical data, including a 23.5-point higher mean change in Bayley-III Cognitive raw score versus an untreated natural-history cohort.
This biotechnology company is expected to post quarterly loss of $0.65 per share in its upcoming report, which represents a year-over-year change of +64.1%. Revenues are expected to be $185.2 million, up 15.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ultragenyx, the consensus EPS estimate for the quarter has been revised 6.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.
Ultragenyx belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) , closed the last trading session 1% higher at $99.02. Over the past month, RYTM has returned -15.3%.
Rhythm Pharmaceuticals' consensus EPS estimate for the upcoming report has changed -2.4% over the past month to -$0.68. Compared to the company's year-ago EPS, this represents a change of +17.1%. Rhythm Pharmaceuticals currently boasts a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx (RARE - Free Report) shares ended the last trading session 12.6% higher at $14.5. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 50.9% loss over the past four weeks.
Shares moved higher following the FDA’s full approval of Ultragenyx’s Fayuvi (rebisufligene etisparvovec-hopf), also known as UX111, for treating the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A) in pediatric patients with preserved neurodevelopmental function. The approval makes Fayuvi the first FDA-approved treatment for this rare and fatal neurodegenerative disorder and marks RARE’s second gene therapy approval and sixth FDA approval overall. The approval was supported by nearly eight years of clinical data, including a 23.5-point higher mean change in Bayley-III Cognitive raw score versus an untreated natural-history cohort.
This biotechnology company is expected to post quarterly loss of $0.65 per share in its upcoming report, which represents a year-over-year change of +64.1%. Revenues are expected to be $185.2 million, up 15.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ultragenyx, the consensus EPS estimate for the quarter has been revised 6.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ultragenyx belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) , closed the last trading session 1% higher at $99.02. Over the past month, RYTM has returned -15.3%.
Rhythm Pharmaceuticals' consensus EPS estimate for the upcoming report has changed -2.4% over the past month to -$0.68. Compared to the company's year-ago EPS, this represents a change of +17.1%. Rhythm Pharmaceuticals currently boasts a Zacks Rank of #2 (Buy).